Navigation Links
Halting bone-building osteoporosis drug use cuts risk for additional atypical femur fracture in half
Date:2/8/2012

SAN FRANCISCO There is growing evidence that supports an association between atypical fractures of the femur a rare break of the thigh bone, typically without trauma and the use of bisphosphonates, drugs proven to enhance bone density and reduce fracture incidence caused by osteoporosis. While the risk for suffering an atypical femur fracture while taking bisphosphonates is still very small just 1 in 1,000 patients after six years of treatment research presented today at the 2012 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) found that discontinuing bisphosphonate use following an atypical femur fracture can significantly lower the risk for a subsequent atypical fracture.

Scientists believe that bisphosphonates may suppress the body's natural process of remodeling -- where old bone tissue is replaced with new, healthy tissue in some patients, resulting in brittle bones susceptible to atypical fractures, especially in the femur.

Investigators reviewed femur fracture data from Jan. 1, 2007 until Dec. 31, 2009 in patients older than 45 enrolled in a large California HMO. There were 126 patients with an atypical femur fracture who reportedly took bisphosphonates prior to their bone break.

The incidence of a subsequent atypical femur fracture occurring in the other thigh was 53.9 percent in patients who continued bisphosphonates for three or more years after their first fracture, compared to 19.3 percent in patients who discontinued bisphosphonate use. Overall, subsequent atypical femur fractures were decreased by 65.6 percent when bisphosphonates were stopped within one year following the first fracture.

"The risk of a contralateral atypical femur fracture (on the opposite side) increases over time if the bisphosphonates are continued," said lead investigator Richard Dell, MD, a researcher in the Department of Orthopaedics at Kaiser Permanente. "Based on these observations, we recommend discontinuing bisphosphonate use as soon as possible after the initial atypical femur fracture has occurred."

Dr. Dell then recommends the ongoing evaluation of these patients, through X-ray or MRI, as they still are at risk for a subsequent, atypical femur fracture on the other femur.

If the patient is at high risk for other fractures, the study recommends use of an alternative osteoporosis medication.


'/>"/>
Contact: Kristina Goel
goel@aaos.org
847-384-4034
American Academy of Orthopaedic Surgeons
Source:Eurekalert

Related medicine news :

1. Molecular playbook for halting heart failure risk factor uncovered
2. Bone-Building Pills Appear to Lower Invasive Breast Cancer Risk
3. Quantity vs. quality: Long-term use of bone-building osteoporosis drugs
4. Early Ovary Removal May Raise Arthritis, Osteoporosis Risk
5. 1st Middle East and Africa Osteoporosis Meeting opens in Dubai
6. Three steps to unbreakable bones on World Osteoporosis Day
7. Capacity to diagnose osteoporosis doubles in Armenia
8. An important breakthrough at the IRCM associated with osteoporosis
9. Bone experts to present strategies for osteoporosis prevention and care in Dubai
10. Osteoporosis Phase III data at 2011 ASBMR Show oral calcitonin tablet is safe and effective
11. FDA Advisers Call for Revised Labels for Osteoporosis Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... Accordant Technology, a ... portfolio. ExtraHop delivers an analytics-first approach, layered with machine learning, that provides real-time ... datacenter to the cloud to the edge. Through the new partnership, customers get ...
(Date:5/24/2017)... Massapequa Park, NY (PRWEB) , ... May 24, ... ... today announced the practice is offering holistic pediatric dentistry options for its patients ... the context of the patient’s entire physical well being, and is one of ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... and nonprofit hospitals and health systems in the nation and help their organizations ... led professional organizations and been instrumental in developing successful hospital and health system ...
(Date:5/24/2017)... , ... May 24, 2017 , ... Technique, technique, technique ... injury when either lifting weights for strength training and exercise or simply lifting heavy ... . , “Body position is everything,” Dr. Chang says. “Improper technique in lifting anything ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... Clinical Integration company, announced today that its iClinic V12.2 solution has achieved approval ... NCQA recently introduced PCMH 2017 standards which emphasize team-based care with a ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)...  Demonstrating its commitment to representing research- based ... Pharmaceutical Research and Manufacturers of America (PhRMA) today ... now have to meet new research and development ... join PhRMA. "By putting in place ... clear message that being a member of PhRMA ...
(Date:5/8/2017)...  Diplomat Pharmacy, Inc. (NYSE: DPLO)., has completed its ... health care service center company based in ... relationship management programs for leading pharmaceutical manufacturers and health ... WRB will join Envoy Health Management, LLC , ... biotech firms, and other service companies. Together, WRB and ...
(Date:5/4/2017)... Fix Inc. (" Fortuna "), a private, clinical-stage biotech ... need for embryonic and fetal stem cells by using direct ... Fortuna announced today the launch of its Scientific ... PhD; Father Kevin FitzGerald , S.J., PhD; Col. (R) ... Giordano , PhD. "We are excited and honored ...
Breaking Medicine Technology: